Literature DB >> 3012186

Inhibitory effect of 1 alpha,25-dihydroxyvitamin D3 on the growth of the renal carcinoma cell line.

K Nagakura, E Abe, T Suda, M Hayakawa, H Nakamura, H Tazaki.   

Abstract

We studied the effect of vitamin D compounds on the growth of the human renal carcinoma cell line (KU-2) and discovered a receptor protein specific for the active form of vitamin D3, 1 alpha,25-dihydroxyvitamin D3. The KU-2 cell line was established from a pulmonary metastasis of renal cell carcinoma in a patient with hyperhemoglobinemia. The cells were tumorigenic in nude mice and clonogenic in a soft agar culture. Vitamin D3 derivatives suppressed proliferation of KU-2 cells in a monolayer culture and also clonogenicity in a soft agar culture dose-dependently. Of the vitamin D3 derivatives tested, 1 alpha,25-dihydroxyvitamin D3 was the most potent in inhibiting cell growth, followed successively by 1 alpha,24R,25-trihydroxyvitamin D3, 25-hydroxyvitamin D3, 1 alpha-hydroxyvitamin D3 and 24R,25-dihydroxyvitamin D3 in that order. Analysis of the cell cycle phase of treated and non-treated KU-2 cells revealed that the action of 1 alpha,25-dihydroxyvitamin D3 was not phase-specific but simply extended the doubling time of the cells. Radioreceptor assay and sucrose density gradient analysis of the cytosol showed that KU-2 cells contained a 3.2S receptor protein to which 1 alpha,25-dihydroxyvitamin D3 was specifically bound (Kd = 20.8 +/- 4.8 pM, Nmax = 87 +/- 24 fmole/mg protein, 4000 molecules/cell). On the other hand, the equilibrium dissociation constant of internalization of 1 alpha,25-dihydroxyvitamin D3 (Kint) by intact KU-2 cells was 1.2 nM and the internalizing capacity was 33 fmole/8 X 10(6) cells (2500 molecules/cell) in the 10% serum medium, which was the same as that used in the growth study.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3012186     DOI: 10.1038/ki.1986.74

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  10 in total

Review 1.  Vitamin D: Implications for ocular disease and therapeutic potential.

Authors:  Rose Y Reins; Alison M McDermott
Journal:  Exp Eye Res       Date:  2015-02-25       Impact factor: 3.467

2.  A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.

Authors:  Kari B Wisinski; Wendy M Ledesma; Jill Kolesar; George Wilding; Glenn Liu; Jeffrey Douglas; Anne M Traynor; Mark Albertini; Daniel Mulkerin; Howard H Bailey
Journal:  J Oncol Pharm Pract       Date:  2014-07-01       Impact factor: 1.809

3.  A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth.

Authors:  James R Lambert; Vikram J Eddy; Christian D Young; Kelly S Persons; Sibaji Sarkar; Julie A Kelly; Elizabeth Genova; M Scott Lucia; Douglas V Faller; Rahul Ray
Journal:  Cancer Prev Res (Phila)       Date:  2010-12

4.  A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis.

Authors:  K Makibayashi; M Tatematsu; M Hirata; N Fukushima; K Kusano; S Ohashi; H Abe; K Kuze; A Fukatsu; T Kita; T Doi
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

Review 5.  Bone and mineral disorders in pre-dialysis CKD.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

6.  Vitamin D: Actions for the new millennium.

Authors:  H Lai; R Pandey; S K Aggarwal
Journal:  Indian J Clin Biochem       Date:  2000-08

7.  Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies.

Authors:  Robert Wieder; Steven C Novick; Bruce W Hollis; Margarette Bryan; Suzanne M Chanel; Kate Owusu; Danielle Camastra; Tracie Saunders; Lillian Pliner; Jonathan Harrison; Peter Bonate; Tom Williams; Steven Soignet
Journal:  Invest New Drugs       Date:  2003-11       Impact factor: 3.850

Review 8.  Vitamin D and urological cancers.

Authors:  Wojciech Krajewski; Mateusz Dzięgała; Anna Kołodziej; Janusz Dembowski; Romuald Zdrojowy
Journal:  Cent European J Urol       Date:  2016-04-19

Review 9.  Vitamin D Receptor: A Novel Therapeutic Target for Kidney Diseases.

Authors:  Shikun Yang; Aimei Li; JianWen Wang; Jun Liu; Yachun Han; Wei Zhang; Yan Chun Li; Hao Zhang
Journal:  Curr Med Chem       Date:  2018       Impact factor: 4.530

10.  Predicted plasma 25-hydroxyvitamin D and risk of renal cell cancer.

Authors:  Hee-Kyung Joh; Edward L Giovannucci; Kimberly A Bertrand; Soo Lim; Eunyoung Cho
Journal:  J Natl Cancer Inst       Date:  2013-04-08       Impact factor: 11.816

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.